c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
1994 · New England Journal of Medicine · 968 citations
https://doi.org/10.1056/nejm199405053301802
D
Daniel R. Budman
Northwell Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
203
Papers
13.5K
Citations
49
h-index
123
i10-index
Daniel R. Budman is an academic researcher from Northwell Health. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & Chronic Lymphocytic Leukemia Research. The author has an h-index of 49, co-authored 173 publications.
Papers by this author
workserbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
1998 · JNCI Journal of the National Cancer Institute · 615 citations
https://doi.org/10.1093/jnci/90.18.1346
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in <i>HER2</i>-Amplified Early Breast Cancer: Results of CALGB 8541/150013
2009 · Journal of Clinical Oncology · 45 citations
https://doi.org/10.1200/jco.2008.18.4085
Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro
2006 · Breast Cancer Research and Treatment · 30 citations
https://doi.org/10.1007/s10549-006-9395-5
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system
2011 · Anti-Cancer Drugs · 24 citations
https://doi.org/10.1097/cad.0b013e32834ebda4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat